CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
45 hedge funds and large institutions have $101M invested in CERo Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 30 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
28.85% less ownership
Funds ownership: 82.39% → 53.54% (-29%)
31% less funds holding
Funds holding: 65 → 45 (-20)
34% less capital invested
Capital invested by funds: $153M → $101M (-$51.9M)
67% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$5.52M |
| 2 |
CC
Centiva Capital
New York
|
+$2.32M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$1.53M |
| 4 |
DCM
Difesa Capital Management
New York
|
+$1.28M |
| 5 |
ETH
Exos TFP Holdings
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$11M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$8.58M |
| 3 |
D.E. Shaw & Co
New York
|
-$7.55M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$4.52M |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$4.38M |
CERO Hedge Fund Activity: Q4 2022 in Review
45 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2022, worth a combined $101M — down 34% from $153M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CERO and 10 opened new positions — a net loss of 20 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $5.52M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $11M sold.
- 45 institutional investors held CERo Therapeutics (CERO) as of Q4 2022, down from 65 in Q3 2022.
- Funds reported $101M of CERo Therapeutics stock for Q4 2022, down 34% quarter-over-quarter.
- 10 funds opened new CERo Therapeutics positions in Q4 2022 and 30 closed out, a net change of -20 holders.
- The largest CERo Therapeutics buyer in Q4 2022 was Beryl Capital Management, an estimated $5.52M added.
- The largest CERo Therapeutics seller in Q4 2022 was Highbridge Capital Management, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2022.